Breast Cancer: E2112 (Hematology Oncology Associates)

CTSU ECOG-ACRIN E2112: A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer


The purpose of this study is find out what effects, both good and bad, an
experimental drug called entinostat has on patients with breast cancer that is not able to be removed by surgery or has spread to another part of the body, when given together with the standard hormonal drug treatment, exemestane.

Despite advances in the treatment of patients with endocrine receptor (ER)-positive breast cancer, many patients fail to respond to an aromatase inhibitor (AI) or suffer recurrence of disease notwithstanding optimal adjuvant therapy. Strategies to overcome resistance to hormonal agents are urgently required in
an effort to improve outcomes for breast cancer patients and delay the time to
chemotherapy use. Histone deacetylase inhibitors are one class of compounds that have been shown to inhibit many of the AI resistance pathways pre-clinically.

Learn more about that trial from the National Cancer Institute

Principal Investigator(s)
Shobha Chitneni

Clinical Trial Categories

  • Cancer
  • Breast Cancer
Cancer Trials Support Unit
Katy D'Aprile, RN, BSN at 563-355-7733


  • University of Iowa Hospital & Clinics, Cancer Center of the Quad Cities
    1351 East Kimberly Road
    Suite 100
    Bettendorf, IA 52722

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office